Add to a list

Inactive Instrument

APRIA Share Price

APR

US03836A1016

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Analysts' recommendations: APRIA

11/01/22	UBS Downgrades Apria to Neutral From Buy, Adjusts Price Target to $37.50 From $41	MT
08/11/21	Citigroup Reinstates Coverage of Apria at Buy with $43 Price Target	MT
05/11/21	UBS Adjusts Price Target on Apria to $41 From $37, Maintains Buy Rating	MT
06/08/21	APRIA : Citigroup Adjusts Apria's Price Target to $38 From $33, Maintains Buy Rating	MT
06/08/21	APRIA : Piper Sandler Adjusts Apria's Price Target to $35 From $33, Maintains Overweight Rating	MT

More recommendations

News in other languages: APRIA

10/01/22	MÄRKTE USA/Kräftige Erholung trotz anhaltender Zinssorgen
10/01/22	MÄRKTE USA/Wall Street mit anhaltenden Zinssorgen unter Druck
10/01/22	MÄRKTE USA/Wall Street mit Verlusten - Steigende Marktzinsen belasten
10/01/22	MÄRKTE USA/Wall Street zu Handelsbeginn mit Abschlägen erwartet

More news

Apria, Inc. is a provider of integrated home healthcare equipment and related services in the United States. The Company offers a range of products and services for in-home care and delivery across three core service lines, which includes home respiratory therapy (including home oxygen and non-invasive ventilation (NIV) services); obstructive sleep apnea (OSA) treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services) and negative pressure wound therapy (NPWT). Additionally, the Company supplies a range of home medical equipment and other products and services for patients with home care needs. It also provides a variety of clinical and administrative support services and related products and supplies. It offers in-home delivery, set-up, and maintenance of equipment and/or supplies; monitoring therapy compliance and intervening to enhance compliance and processing claims to payors on behalf of patients.

Employees

6,250

Sector

More about the company

30/03/22	Apria, Inc.(NasdaqGS:APR) dropped from S&P Global BMI Index	CI
30/03/22	Apria, Inc.(NasdaqGS:APR) dropped from S&P TMI Index	CI
29/03/22	Apria, Inc. Announces Management Changes	CI
29/03/22	Apria, Inc.(NasdaqGS:APR) dropped from NASDAQ Composite Index	CI
28/03/22	Byram Healthcare Centers, Inc. completed the acquisition of Apria, Inc. from Blackstone Inc. (NYSE:BX), John G. Figueroa and Daniel J. Starck and others.	CI
23/03/22	Owens & Minor Prices Upsized $600 Million Placement of 6.625% Notes Due 2030 for Apria Acquisition	MT
18/03/22	Owens & Minor to Raise $500 Million via Private Offering of Senior Notes	MT
03/03/22	Insider Sell: Apria	MT
28/02/22	Apria, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	CI
28/02/22	Earnings Flash (APR) APRIA Reports Q4 Revenue $296.5M	MT
11/01/22	S&P Revises Owens & Minor Outlook To Stable From Positive On Acquisition Of Apria Health, Ratings Affirmed	MT
11/01/22	UBS Downgrades Apria to Neutral From Buy, Adjusts Price Target to $37.50 From $41	MT
10/01/22	Top Midday Gainers	MT

29/03/22	APRIA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
24/03/22	APRIA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
14/03/22	APRIA, INC. : Other Events (form 8-K)	AQ
02/03/22	APRIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apria, Inc. - APR	BU
01/03/22	APRIA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ

Manager	Title	Age	Since
Daniel Starck CEO	Chief Executive Officer	59	-
Mark Litkovitz CTO	Chief Tech/Sci/R&D Officer	-	-
Christopher G. Lee AUD	Comptroller/Controller/Auditor	45	31/01/2009

Director	Title	Age	Since
Daniel Starck BRD	Director/Board Member	59	-
Andrew Long BRD	Director/Board Member	60	28/03/2022
Nicholas Pace BRD	Director/Board Member	55	28/03/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/03/22	Norman Payson	Issuer sale	Director	5,059	0.0142%
28/03/22	Christopher G. Lee	Issuer sale	Controller/Auditor	56,398	0.1582%
28/03/22	Angela Fyfe	Issuer sale	Executive/Senior Manager	206,149	0.5783%

APRIA Share Price

Stocks

APR

US03836A1016

Latest news : APRIA

Analysts' recommendations: APRIA

Press Releases: APRIA

News in other languages: APRIA

Quotes and Performance

Managers and Directors: APRIA

Latest insider transactions

Company Profile